366 related articles for article (PubMed ID: 30865033)
21. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
22. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
23. Molecular Targets Beyond the Big 3.
Reckamp KL
Thorac Surg Clin; 2020 May; 30(2):157-164. PubMed ID: 32327174
[TBL] [Abstract][Full Text] [Related]
24. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T; Takahashi F; Takahashi K
Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
[TBL] [Abstract][Full Text] [Related]
25. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
Chen N; Tyler LC; Le AT; Welsh EA; Fang B; Elliott A; Davies KD; Danhorn T; Riely GJ; Ladanyi M; Haura EB; Doebele RC
Mol Cancer Ther; 2024 Jan; 23(1):92-105. PubMed ID: 37748191
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
27. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
28. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo G; Facchinetti F; Olaussen KA; Besse B; Friboulet L
Nat Rev Clin Oncol; 2018 Nov; 15(11):694-708. PubMed ID: 30108370
[TBL] [Abstract][Full Text] [Related]
29. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
[TBL] [Abstract][Full Text] [Related]
31. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
32. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
33. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
34. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
36. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
37. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy for lung cancer: Beyond EGFR and ALK.
Herrera-Juárez M; Serrano-Gómez C; Bote-de-Cabo H; Paz-Ares L
Cancer; 2023 Jun; 129(12):1803-1820. PubMed ID: 37073562
[TBL] [Abstract][Full Text] [Related]
39. Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.
Yoda S; Dagogo-Jack I; Hata AN
Pharmacol Ther; 2019 Jan; 193():20-30. PubMed ID: 30121320
[TBL] [Abstract][Full Text] [Related]
40. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]